ABVc BioPharma(OTCMKTS：ABVc-GET Rating)是「藥物製劑」行業的946家上市公司之一，但它與競爭對手相比有何不同？我們將根據ABVC BioPharma的風險、估值、分析師建議、盈利能力、股息、機構所有權和收益的實力，將其與相關公司進行比較。
熱門資訊> 正文
ABVc BioPharma(ABVC)及其競爭對手的關鍵對比
2022-07-05 16:11
ABVC BioPharma (OTCMKTS:ABVC – Get Rating) is one of 946 public companies in the "Pharmaceutical preparations" industry, but how does it contrast to its competitors? We will compare ABVC BioPharma to related companies based on the strength of its risk, valuation, analyst recommendations, profitability, dividends, institutional ownership and earnings.
Valuation and Earnings
估值和收益
Get
到達
ABVC BioPharma
ABVc生物製藥
alerts:
警報：
This table compares ABVC BioPharma and its competitors revenue, earnings per share (EPS) and valuation.
該表格比較了ABVC BioPharma及其競爭對手的收入、每股收益(EPS)和估值。
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| ABVC BioPharma | $360,000.00 | -$12.84 million | -1.53 |
| ABVC BioPharma Competitors | $1.85 billion | $247.89 million | -2.52 |
| 總收入 | 淨收入 | 市盈率 | |
| ABVc生物製藥 | $360,000.00 | -1,284萬元 | -1.53 |
| ABVc BioPharma競爭對手 | 18.5億美元 | 2.4789億美元 | -2.52 |
ABVC BioPharma's competitors have higher revenue and earnings than ABVC BioPharma. ABVC BioPharma is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
ABVc BioPharma的競爭對手比ABVC BioPharma的收入和收益更高。ABVc BioPharma的市盈率高於競爭對手，這表明它目前的價格高於同行業的其他公司。
Volatility & Risk
波動性與風險
ABVC BioPharma has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500. Comparatively, ABVC BioPharma's competitors have a beta of 1.05, suggesting that their average stock price is 5% more volatile than the S&P 500.
ABVc BioPharma的貝塔係數為0.97，這表明其股價的波動性比標準普爾500指數低3%。相比之下，ABVC BioPharma的競爭對手的貝塔係數為1.05，這表明它們的平均股價波動性比標準普爾500指數高出5%。
Profitability
盈利能力
This table compares ABVC BioPharma and its competitors' net margins, return on equity and return on assets.
此表比較了ABVC BioPharma及其競爭對手的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| ABVC BioPharma | N/A | -287.25% | -148.54% |
| ABVC BioPharma Competitors | -3,134.90% | -136.35% | -9.11% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| ABVc生物製藥 | 不適用 | -287.25% | -148.54% |
| ABVc BioPharma競爭對手 | -3,134.90% | -136.35% | -9.11% |
Insider & Institutional Ownership
內部人與機構所有權
1.6% of ABVC BioPharma shares are held by institutional investors. Comparatively, 45.7% of shares of all "Pharmaceutical preparations" companies are held by institutional investors. 43.4% of ABVC BioPharma shares are held by company insiders. Comparatively, 15.0% of shares of all "Pharmaceutical preparations" companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
ABVC BioPharma 1.6%的股份由機構投資者持有。相比之下，所有「醫藥製劑」公司45.7%的股份由機構投資者持有。ABVC BioPharma 43.4%的股份由公司內部人士持有。相比之下，所有「醫藥製劑」公司15.0%的股份由公司內部人持有。強大的機構持股表明，對衝基金、捐贈基金和大型基金管理公司相信，一家公司的長期表現將好於大盤。
Analyst Ratings
分析師評級
This is a breakdown of recent recommendations for ABVC BioPharma and its competitors, as provided by MarketBeat.com.
這是最近由MarketBeat.com提供的對ABVC BioPharma及其競爭對手的建議的細目。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ABVC BioPharma | 0 | 0 | 0 | 0 | N/A |
| ABVC BioPharma Competitors | 2679 | 12385 | 38528 | 609 | 2.68 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| ABVc生物製藥 | 0 | 0 | 0 | 0 | 不適用 |
| ABVc BioPharma競爭對手 | 2679 | 12385 | 38528 | 609 | 2.68 |
As a group, "Pharmaceutical preparations" companies have a potential upside of 115.45%. Given ABVC BioPharma's competitors higher probable upside, analysts plainly believe ABVC BioPharma has less favorable growth aspects than its competitors.
作為一個整體，「藥物製劑」公司有115.45%的潛在上行空間。考慮到ABVC BioPharma的競爭對手更有可能上行，分析師們顯然認為ABVC BioPharma在增長方面不如競爭對手。
Summary
摘要
ABVC BioPharma competitors beat ABVC BioPharma on 7 of the 10 factors compared.
ABVc BioPharma的競爭對手在比較的10個因素中有7個擊敗了ABVC BioPharma。
About ABVC BioPharma (Get Rating)
關於ABVC BioPharma(獲取評級)
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
ABVc BioPharma，Inc.是一家臨牀階段的生物製藥公司，開發藥物和醫療設備，以滿足美國未得到滿足的醫療需求。該公司正在開發ABV-1501，這是一種治療三陰性乳腺癌的聯合療法，處於I/II期臨牀試驗；ABV-1504已經完成了針對嚴重抑郁症的第二階段臨牀試驗；ABV-1505正在進行注意力缺陷多動障礙的第二階段臨牀試驗；ABV-1703已經完成了治療胰腺癌的第一階段臨牀試驗；ABV-1702已經完成了治療骨髓增生異常綜合徵的第一階段臨牀試驗；ABV-1601正在進行治療癌症患者抑郁的I/II期臨牀試驗；以及ABV-1701用於治療視網膜脱離或玻璃體出血的ABV-1701。它與Rgene Corporation簽訂了共同開發協議，並與BioHopeKing Corporation和BioFirst Corporation簽訂了合作協議。該公司總部設在加利福尼亞州弗里蒙特。ABVc BioPharma，Inc.是袁基因公司的子公司。
Receive News & Ratings for ABVC BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABVC BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
獲得ABVC BioPharma Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對ABVC BioPharma和相關公司的最新新聞和分析師評級的每日簡要摘要。
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
